Peripheral T-cell lymphoma
Showing 26 - 50 of >10,000
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma Trial in Chicago (Fenretinide)
Not yet recruiting
- T-cell Lymphoma
- +10 more
-
Chicago, IllinoisRush University Medical Center
Oct 24, 2022
Peripheral T-cell Lymphoma Trial in Tianjin (Lposomal mitoxantrone HCl,Cyclophosphamide,Vincristine,Etoposide and
Not yet recruiting
- Peripheral T-cell Lymphoma
- Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Insititute & Hospital
Jul 13, 2022
Peripheral T Cell Lymphoma Trial in Harlingen (Belinostat Injection, Pralatrexate Injection, CHOP)
Not yet recruiting
- Peripheral T Cell Lymphoma
- Belinostat Injection
- +3 more
-
Harlingen, TexasValley Cancer Associates
Oct 16, 2023
Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides Trial in United
Recruiting
- Folliculotropic Mycosis Fungoides
- +7 more
- Durvalumab
- +2 more
-
Duarte, California
- +3 more
Jan 12, 2023
Peripheral T Cell Lymphoma Trial in Zhejiang (Mitoxantrone liposome?Chidamide?Azacitidine)
Recruiting
- Peripheral T Cell Lymphoma
- Mitoxantrone liposome、Chidamide、Azacitidine
-
Zhejiang, Zhejiang, ChinaSecond Affiliated Hospital, School of Medicine, Zhejiang Univers
Aug 9, 2022
Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell
Recruiting
- Recurrent Angioimmunoblastic T-Cell Lymphoma
- +13 more
- Brentuximab Vedotin
- Pembrolizumab
-
Chicago, IllinoisNorthwestern University
Jun 15, 2022
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell
Active, not recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +10 more
- Pembrolizumab
- Romidepsin
-
Houston, TexasM D Anderson Cancer Center
Jan 30, 2023
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)
Not yet recruiting
- Relapsed or Refractory Hodgkin Lymphoma
- Peripheral T Cell Lymphoma
- AFM13
- +4 more
- (no location specified)
May 30, 2023
Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Fairport (Tolinapant, Decitabine + Cedazuridine)
Recruiting
- Relapsed/Refractory Peripheral T-cell Lymphoma
- Tolinapant
- Decitabine + Cedazuridine
-
Aurora, Colorado
- +2 more
Jan 3, 2023
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma
Recruiting
- Anaplastic Large Cell Lymphoma
- +19 more
- Pembrolizumab
- Pralatrexate
-
Duarte, California
- +2 more
Aug 15, 2022
Peripheral T-Cell Lymphoma, Lenalidomide, CHOP Trial in Hangzhou (Lenalidomide, Cyclophosphamide, Doxorubicin)
Recruiting
- Peripheral T-Cell Lymphoma
- +2 more
- Lenalidomide
- +4 more
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 3, 2022
Allo-HSCT as First-line Consolidation in High-risk PTCL
Recruiting
- T Cell Lymphoma
-
Beijing, ChinaPeking University People's Hospital
Jul 31, 2022
Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,
Recruiting
- Cutaneous T-Cell Lymphoma
- +3 more
- Romidepsin
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) Trial (Tipifarnib)
Available
- HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
- (no location specified)
Jun 7, 2022
T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in Italy (Venetoclax)
Active, not recruiting
- T-Cell Lymphoma Relapsed
- T-Cell Lymphoma Refractory
-
Aviano, Italy
- +12 more
Dec 20, 2022
Treatment, Peripheral T-cell Lymphoma Trial in Beijing (liposomal mitoxantrone HCl, gemcitabine, dexamethasone, and cisplatin)
Recruiting
- Treatment
- Peripheral T-cell Lymphoma
- liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
-
Beijing, China
- +4 more
Jun 28, 2022
Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma Trial in Boston (Microdevices, Standard of care therapy, Standard of care
Recruiting
- Cutaneous T Cell Lymphoma
- Peripheral T Cell Lymphoma
- Microdevices
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Jul 16, 2022
Peripheral T Cell Lymphoma Trial in Houston (Tenalisib)
Withdrawn
- Peripheral T Cell Lymphoma
-
Houston, TexasThe University of Texas MD Anderson Cancer Center
Oct 13, 2022
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)
Not yet recruiting
- T-Cell Non-Hodgkin Lymphoma
- +14 more
- WU-CART-007
-
Saint Louis, MissouriWashington University School of Medicine
Jan 17, 2023
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- +4 more
- anti-CD7 CAR-T cells
-
Shanghai, ChinaXianmin General Song
Aug 29, 2022
T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail
Recruiting
- T-cell Lymphoma
- +30 more
- Optional Blood Sample
- Optional Nail Sample
-
Duarte, California
- +25 more
Jul 28, 2023